Acer Therapeutics new article on Seeking Alpha Jan 31 2020See
https://seekingalpha.com/article/4320604-acer-therapeutics-upcoming-catalysts
"...
Acer has a number of upcoming catalysts including a possible positive appeal outcome for EDSIVO which could be known by end of Q1 2020. The chances of a positive appeal outcome for ACER arising out of its appeal filed with the FDA from the June 24th CRL is estimated by me to be higher than 50%, and perhaps as high as 70%. In defining a positive or successful resolution, I am including both a full CRL reversal (less likely) but also including a resolution with the FDA in which a more reasonable path forward to approval of EDSIVO in the U.S. for the treatment of vEDS with a COL3A1+ mutation is determined, short of the currently required full-blown Phase 3 double-blind study being set out in the June 24th CRL.
Given Acer's current $43 million market cap, and the potential $250 million to $400 million in peak annual sales that EDSIVO could generate in the U.S. if approved, a successful appeal or reasonable resolution of the EDSIVO CRL could be a major catalyst for Acer's share price. This is true even with Acer likely requiring additional equity financing later this year.
Investors in Acer could learn the initial results of Acer's FDRR appeal process for EDSIVO by the end of Q1 2020.
A successful outcome from the appeal could materially increase Acer's share price, which would, in turn, allow Acer to raise capital at much higher share prices compared to today's current valuations which would, in turn, allow Acer to pursue EDSIVO and its other pipeline opportunities. ..."